$CAMP

Camp4 Therapeutics Corp

Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics designed to increase gene expression and restore protein levels for genetic diseases. Its proprietary RAP Platform identifies regulatory RNAs and supports the design of antisense oligonucleotide medicines. The company’s pipeline includes CMP-002, an intrathecally delivered candidate for SYNGAP1-related disorder, and CMP-001, a candidate for urea-cycle disorders that has completed a Phase 1 trial in healthy volunteers. Camp4 also advances discovery programs in other developmental and epileptic encephalopathy indications and collaborates with GlaxoSmithKline on research and development targeting neurodegenerative and kidney disease indications. Camp4’s candidates are at research and clinical development stages; it relies on third-party contract manufacturers and service providers for product manufacture and related activities. Under its collaboration with GlaxoSmithKline, Camp4 conducts research and transfers lead candidate series and related data, while GlaxoSmithKline is responsible for subsequent development, manufacturing and commercialization of licensed products. Camp4 Therapeutics is headquartered in Watertown, Massachusetts.

0
1
0

No SEC Form 4 filings for $CAMP in the last 30 days.

See all $CAMP insider activity →
Low

CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears

CAMP4 Therapeutics plans to start patient dosing for its SYNGAP1 treatment, CMP-002, by year-end and report initial data in early 2028. The Phase 1/2 trial will evaluate safety and potential efficacy signals, but not establish efficacy. The company has $124.5 million in cash, expected to fund operations through 2028, including the SYNGAP1 readout and other programs.

Camp4 Therapeutics GAAP EPS of -$0.37 (NASDAQ:CAMP)

Camp4 Therapeutics reported a Q3 GAAP EPS of -$0.37, missing estimates by $0.37. The company had $124.5M in cash and equivalents as of September 30, 2026, up from $109.5M at the end of 2025. The earnings report was released on November 6, 2026.

CAMP4 receives EU approval for CMP-002 SYNGAP1 disorder trial

CAMP4 Therapeutics (NASDAQ:CAMP) received EU approval to begin Phase 1/2 trial of CMP-002 for SYNGAP1 disorder. The company plans to dose the first patient in Q4 2026. CMP-002 is an antisense oligonucleotide designed to increase SYNGAP1 gene expression. CAMP4 has previously received approvals in Australia, Argentina, and the UK.

CAMP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning CAMP (Camp4 Therapeutics Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent CAMP coverage spans financial news, insider activity and regulation.

What's driving CAMP

  • CAMP4 Therapeutics plans to start patient dosing for its SYNGAP1 treatment, CMP-002, by year-end and report initial data in early 2028. The Phase 1/2 trial will evaluate safety and potential efficacy signals, but not establish efficacy. The company has $124.5 million in cash, expected to fund operations through 2028, including the SYNGAP1 readout and other programs.

    finance.yahoo.com · Nov 10, 2026

  • The earnings miss suggests downward pressure on the stock.

    seekingalpha.com · Nov 6, 2026

  • Regulatory clearance enables first-in-human trial, likely boosting investor sentiment.

    investing.com · Oct 27, 2026

  • Analyst upgrade to Strong Buy with a high price target.

    investing.com · Oct 23, 2026

  • Analyst upgrade and aggressive price target are likely to attract buying interest.

    tradingview.com · Oct 15, 2026

AlphAI scores every news story that mentions CAMP with an AI model for sentiment and relevance, and aggregates insider trades from Camp4 Therapeutics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CAMP

Score

CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears

CAMP4 Therapeutics plans to start patient dosing for its SYNGAP1 treatment, CMP-002, by year-end and report initial data in early 2028. The Phase 1/2 trial will evaluate safety and potential efficacy signals, but not establish efficacy. The company has $124.5 million in cash, expected to fund operations through 2028, including the SYNGAP1 readout and other programs.

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics (Nasdaq: CAMP) received UK authorization to include sites in its Phase 1/2 trial for CMP-002, a potential treatment for SYNGAP1-related disorder. The company plans to start the trial in 4Q 2026, following clearances in Australia and Argentina. CMP-002 aims to restore SYNGAP protein levels, with no approved therapies currently available for this rare disorder.

Related tickers